Summary
Corteva, Inc. reported mixed results for the second quarter and first half of 2026. Net sales saw a slight decrease of 1% in Q2 2026 compared to Q2 2025, driven by lower volumes, but a 4% increase for the first half of 2026 compared to the same period in 2025, benefiting from favorable currency impacts and volume growth. Net income attributable to Corteva was $1,161 million for Q2 2026, down from $1,314 million in the prior year quarter, reflecting the overall sales trend and increased expenses. For the first half of 2026, net income was $1,881 million, down from $1,966 million in the prior year period. Operationally, the company announced its intent to separate into two independent, publicly traded companies focusing on its Seed and Crop Protection businesses, a significant strategic development. Restructuring charges related to this intended separation and ongoing optimization programs were noted. The company also continues to manage substantial litigation and environmental liabilities, particularly concerning PFAS, which impacted discontinued operations. Key financial movements include a significant decrease in cash and cash equivalents from the prior year-end, largely due to operational activities and strategic payments. The company's liquidity remains strong, supported by credit facilities and access to capital markets.
Key Highlights
- 1Announced intent to separate into two independent companies (Seed and Crop Protection businesses) in October 2025.
- 2Q2 2026 Net Sales decreased 1% to $6,379 million, while first half 2026 Net Sales increased 4% to $11,284 million.
- 3Q2 2026 Net Income attributable to Corteva decreased to $1,161 million from $1,314 million in Q2 2025.
- 4Total operating EBITDA for Q2 2026 was $2,261 million, an increase from $2,164 million in Q2 2025.
- 5Significant ongoing restructuring actions are underway, impacting financial results.
- 6Cash and cash equivalents decreased significantly to $2,365 million as of June 30, 2026, from $4,521 million at December 31, 2025.
- 7The company resolved its outstanding litigation with Bayer and made a substantial payment related to this resolution.